Nominations for the 2014 award are now closed.
The winner for the 2014 award will be announced in January 2014.
The Award and Lecture
This award was established in 1996 to recognize outstanding achievements in clinical cancer research. It is named for the late Dr. Joseph H. Burchenal, honorary member and past president of the AACR, and a major figure in clinical cancer research and chemotherapy.
The winner of the 19th Annual AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research will give a 50-minute lecture during the AACR Annual Meeting 2014, in San Diego, CA, USA (April 5-9, 2014), receive an honorarium of $10,000, and will be given support for the winner and a guest to attend the Annual Meeting.
- Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
Nomination Procedure and Instructions
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Nominations must be submitted online at https://proposalcentral.altum.com/ by 4:00 p.m. United States Eastern Time on Thursday, October 24, 2013. Paper nominations will not be accepted.
Nomination materials to be submitted are:
1) Nomination Letter Must:
- be addressed to the Selection Committee; be written in English; and not exceed 1,000 words;
- specify the AACR Award for which the candidate is being nominated;
- contain a concise description of the candidate's outstanding achievements in clinical cancer research; publications supporting these contributions must be directly referenced within the letter;
- contain a concise description of the impact of these contributions on the field; and
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Full nomination instructions and program guidelines are available through the link below and on the proposalCENTRAL website.
Program Guidelines and Nomination Instructions. Download the Adobe Acrobat Reader here.
Candidates will be considered by a Selection Committee of international cancer leaders appointed by the president of the AACR. After careful deliberations by the committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate's achievements in clinical cancer research. No regard will be given to age, race, gender, nationality, geographic location or religious or political views.
Generously supported by Bristol-Myers Squibb.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
18th Annual Award Recipient
Hagop M. Kantarjian, M.D.
Professor of Medicine
Chairman, Department of Leukemia
UT MD Anderson Cancer Center
Dr. Kantarjian delivered his award lecture titled Leukemia Research and Progress - A Look Back at the Future
, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Tuesday, April 9, 2013. Visit the AACR Annual Meeting 2013
page for more information on the Annual Meeting.
Dr. Hagop M. Kantarjian is honored for his pioneering clinical-translational research, and his numerous seminal discoveries that have improved the prognosis in several leukemia categories including CML, ALL, AML and MDS.
Dr. Kantarjian is the Kelcie Margaret Kana research chair in the leukemia department and associate vice president for global academic programs at The University of Texas MD Anderson Cancer Center, has contributed to numerous changes in the treatment of patients with several forms of leukemia. For example, he was a leader in the development and testing of both the first- and second-generation inhibitors of the BCR-ABL protein that drives nearly all cases of chronic myeloid leukemia. These treatments significantly reduced the annual mortality rate for patients with chronic myeloid leukemia from 10 to 15 percent, to 1 to 2 percent.
His research on acute lymphoid leukemia led to several advances in patient care, including the establishment of standard-of-care treatment for patients diagnosed with the disease, and the U.S. Food and Drug Administration (FDA) approval of clofarabine for children with acute lymphoid leukemia that has recurred after, or failed to respond to, initial treatment.
In addition, Dr. Kantarjian’s research established the efficacy of epigenetic therapy for myelodysplastic syndrome, a disease that frequently develops into acute myeloid leukemia, and led to the concept of low-intensity therapy for patients older than 70 with acute myeloid leukemia. He also led the clinical trial that resulted in the January 2012 FDA approval of ruxolitinib for myelofibrosis, a type of chronic leukemia for which there was no specific treatment. In addition to being the first drug approved for myelofibrosis, ruxolitinib was the first drug targeting the cancer-driving protein JAK2 to be approved by the FDA.
Dr. Kantarjian’s significant contributions to the leukemia community extend far beyond his own research achievements. He has established a world-renowned department of leukemia at The University of Texas MD Anderson Cancer Center and mentored many internationally recognized experts in the field of clinical leukemia research.
Dr. Kantarjian received his medical degree from The American University of Beirut in Lebanon and subsequently completed a fellowship at The University of Texas MD Anderson Cancer Center. He has received several accolades throughout his career, including the Outstanding Service to Mankind Award from the Leukemia Society of America.
Dr. Kantarjian, a member of the AACR since 1985, is on the editorial board of Clinical Cancer Research. He is also a member of several other professional organizations, including the American Association for the Advancement of Sciences, the American Society for Clinical Oncology and the American Society for Hematology.